Sloan AR, Thapliyal M, Lathia JD. New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat.
Clin Cancer Res 2024;
30:477-479. [PMID:
38038689 PMCID:
PMC10842869 DOI:
10.1158/1078-0432.ccr-23-3051]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 11/10/2023] [Accepted: 11/21/2023] [Indexed: 12/02/2023]
Abstract
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized cancer therapy for some advanced cancers, but success is predicated on identifying the correct cell surface target. In a recent article, the authors leveraged the cancer stem cell surface antigen CD133 to develop a CAR-T therapy for brain metastasis. See related article by Kieliszek et al., p. 554.
Collapse